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ABSTRACT
Clinical experience and animal models have shown that donor T cell depletion (TCD) adversely affects
engraftment of hematopoietic stem cells (HSCs). Although it is known that donor T cells are acting to
overcome residual host immune barriers, they may also exert effects independent of host resistance via direct
or indirect interactions with donor stem cells, their microenvironment, or key differentiation events. To more
precisely define the effect of T cells on engraftment, we have performed human umbilical cord blood (UCB)
transplantation into immunodeficient mice under limiting dilution conditions. UCB mononuclear cells (MNC)
or TCD UCB were transplanted into NOD/LtSz-scid/scid B2mnull (NOD/SCID-2m
/) mice. Cohorts of
mice received UCB MNC or TCD UCB at 5 dose levels between 5  104 and 5  106 cells. At dose levels at
or above 105 cells, engraftment was higher in the MNC recipients (n  32) than the TCD recipients (n  31)
in a dose-dependent manner. Despite this difference, limiting dilution analysis to determine functional stem
cell frequency revealed that SCID repopulating cells in TCDUCB was not significantly less than in CBMNCs,
suggesting that T cells may facilitate engraftment at stages beyond the stem cell. Add-back of CD3/CD28
costimulated T cells restored and appeared to enhance engraftment, both in NOD/SCID-2m
/ as well as
NOD/LtSz-scid IL2Rnull (NOG) recipients. These results, in a model where there are minimal host immune
barriers to overcome, suggest T cells possess additional graft-facilitating properties. CD3/CD28 costimulation
of UCB T cells represents a potential strategy for enhancing the engraftment of UCB.
© 2007 American Society for Blood and Marrow Transplantation
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An attractive property of umbilical cord blood
UCB) as a graft for hematopoietic stem cell trans-
lantation (HSCT) is the reduced incidence of acute
raft-versus-host disease (aGVHD) when compared
o blood or marrow stem cell sources, despite the use
f UCB grafts that are frequently mismatched at 1 or
ore major histocompatibility (MHC) locus. This
eature of UCB is thought, in part, to be mediated by
niquely tolerant naive T cells in UCB grafts [1,2].
lthough this increased tolerance to MHC mismatch- eng makes UCB an attractive graft phenotype, UCB is
low to engraft, representing a major limitation to the
roader application of UCB HSCT in Western coun-
ries. The slow kinetics of engraftment are known to
e profoundly inﬂuenced by the absolute numbers of
ononuclear cells (MNCs) in UCB grafts, but even
bove acceptable threshold numbers of cells, recipi-
nts of UCB grafts remain neutropenic and thrombo-
ytopenic signiﬁcantly longer than recipients of other
nrelated HSC sources [3-5]. Three possible explana-
ions for the empiric evidence are: (1) there are not
nough hematopoietic stem cells (HSCs) in UCB
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E. O. Hexner et al.1136rafts (intrinsic, quantitative defect in HSCs); (2)
CB HSCs are intrinsically less able and/or more
low to repopulate the HSC niche (intrinsic, qualita-
ive defect in HSCs); or (3) nonhematopoietic, acces-
ory cells in the UCB graft are less able to facilitate the
ngraftment and/or differentiation of UCB HSCs (de-
ect extrinsic to UCB HSCs). In the last case, 1 can-
idate “defective” graft facilitating accessory cell is the
CB T cell. That is, the unique properties of UCB T
ells that render UCB a better tolerated donor graft
ay at the same time be responsible for the delayed
ngraftment of UCB HSCs. If true, graft engineering
f T cells in UCB could accelerate UCB engraftment.
From an experimental perspective, immunodeﬁ-
ient mouse models provide a useful system to dissect
he relative importance of these 2 mechanisms: be-
ause host barriers are absent, if donor T cells fail to
mplify engraftment, this suggests that their primary
ole in HSCT is to overcome barriers. On the other
and, if T cells maintain a graft-facilitating effect in
hese immunodeﬁcient mice, this implies that T cells
ctively facilitate grafts beyond defending against host
mmune cells. Mouse models with progressively lower
mmune barriers have been developed over the last
everal decades. Scid/scid mice lacking T and B cells
ere the ﬁrst immunodeﬁcient mice shown to support
ymphoid development of adoptively transferred hu-
an fetal liver cells following the implantation of
uman fetal thymus (the so-called SCID-hu mouse),
lthough levels of engraftment were low, because of in
arge part to the presence of natural killer (NK) cells
6,7]. NOD/LtSz-scid/scid (NOD/SCID) mice have
educed numbers of NK cells and represented a sig-
iﬁcant advance for in vivo functional stem cell assays
ecause they support myeloid and lymphoid develop-
ent of human hematopoietic cells [8,9]. The low
evel of residual NK activity in NOD/SCID mice can
e augmented by pyrogens like poly(I:C), and might
till represent a signiﬁcant barrier to transplantation
ollowing sublethal irradiation [6]. Engraftment was
nhanced approximately 10-fold when these mice
ere crossed with mice null for the 2 microglobulin
llele. The NOD/SCID-2m
/ lacks cell surface
lass I molecules and NK cells, even in response to
oly(I:C) [6,10]. Although NOD/SCID-2m
/ mice
ave monocytes and macrophages that may yet repre-
ent a minimal barrier to xenotransplantation, they
epresent an improved strain for supporting human
enografts, excluding antibody pretreated animals
11]. Recent derivation of the NOD/LtSz-scid
L2Rnull (NOG) mouse has shown outstanding mul-
ilineage engraftment of human cells, and may be the
est current murine xenograft model [12].
If the predominantly naïve T cells in UCB under-
ie the engraftment delay in UCB HSCT, it may be
ossible to activate UCB T cells to accelerate engraft-
ent. CD3 and CD28 stimulatory antibodies immo- tilized on magnetic beads deliver the required co-
timulatory signals for T cell activation and expansion,
nd can result in the large-scale expansion of poly-
lonal CD4 and CD8 T cells, with a preserved T
ell receptor (TCR) repertoire [13]. The feasibility
nd clinical safety of delayed infusion of these cells has
ow been demonstrated in the autologous as well as
he allogeneic setting; studies using CD3/CD28 co-
timulated UCB T cells at the time of HSCT or as
elayed infusions have not been reported to date, but
epresent a potential approach to improving engraft-
ent and/or graft-versus-tumor activity [14-16].
In this study we sought to directly test the speciﬁc
ole of mature UCB T cells on engraftment of UCB
ndependent of their T cell effects overcoming immune
arriers. Using NOD/SCID-2m
/ and NOG mice as
ecipients of human UCB grafts, we have found that
rafts depleted of T cells (TCD) have inferior levels of
ngraftment when compared to UCB MNCs trans-
lanted into NOD/SCID-2m
/ mice. Although the
verall level of engraftment was signiﬁcantly lower for
OD/SCID-2m
/ recipients of TCD UCB, SCID
epopulating cell (SRC) frequency was not signiﬁcantly
ecreased per se. Engraftment capacity was restored and
nhanced by add-back of ex vivo CD3/CD28 costimu-
ated T cells from the same UCB unit. Our results
uggest that T cells facilitate engraftment beyond simply
vercoming host barriers, and that CD3/CD28 costimu-
ated UCB T cells possess graft-promoting properties,
epresenting a potential translational approach for facil-
tating engraftment in UCB HSCT.
ATERIALS AND METHODS
nimals
NOD/LtSz-scid/scid B2mnull mice and NOD/
tSz-scid IL2Rnull (Jackson Laboratory, Bar Harbor,
E) were maintained in an animal facility at the
niversity of Pennsylvania with approval of the Insti-
utional Animal Care and Use Committee. Trans-
lanted animals were maintained in microisolators
ith water supplemented with polymixin B sulfate
1000 U/mL) and neomycin sulfate (1.1 mg/mL).
ell Preparations
UCB was obtained from placentas from full-term
cheduled Cesarean section births at the Hospital of
he University of Pennsylvania under an institutional
eview board exempted protocol. Mononuclear cells
ere isolated on a Ficoll-Paque PLUS (Amersham
iosciences, Arlington Heights, IL) density gradient
nd cryopreserved until the day of xenotransplanta-
ion. A single UCB unit was used for limiting dilution
nalysis. Two additional UCB units were used in 2
eparate experiments to test the engraftment proper-
ies of CD3/CD28 costimulated T cells (3 groups:
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D28 costimulated T cells). HLA types of the UCB
nits were not known. Activated T cells from a UCB
nit was always infused with TCD UCB from the
ame unit; and UCB MNC or TCD UCB groups
rom the same experiment received cells from the
ame unit as well. Prior to transplantation, UCB
NCs were thawed; the TCD preparations were de-
leted of T cells via CD2 immunomagnetic selection
Dynabeads M-450 CD2, Dynal Biotech, Bath, UK)
ccording to the manufacturer’s protocol. Efﬁciency
f depletion was determined by Fluorescence Acti-
ated Cell Sorting (FACS) analysis prior to infusion.
or all infused cells, cell number and viability was
etermined by trypan blue exclusion immediately
rior to infusion; all infused cells were suspended in
BS (250 L/mouse).
To prepare CD3/CD28 costimulated T cells, cells
ere isolated from an aliquot of freshly collected UCB
rior to the cryopreservation of the UCB unit. CD4
nd CD8 T cells were enriched separately from 2.5
L of UCB (RosetteSep, StemCell Technologies,
anada) according to the manufacturer’s protocol.
ells were plated and maintained at a cell density of 1
illion/mL in RPMI 1640 supplemented with 2 mM
-Glutamine, 25 mM HEPES, 100 U/mL Penicillin,
00 g/mL Streptomycin (Life Technologies, Balti-
ore, MD), and 10% fetal bovine serum (Gemini
io-Products, Calabasas, CA). For the ﬁrst 72 hours,
ells were cocultured with Dynabeads coated with
nti-CD3 and anti-CD28 monoclonal antibodies
mAb) at a ratio of 3 beads per cell [13]. Beads were
emoved magnetically after 72 hours of culture, and
n days 7-9 cells were washed twice in PBS prior to
nfusion. Conﬁrmation that T cells were activated as
rst described by Levine et al. [13] using this culture
rotocol was conﬁrmed by increased cell surface ex-
ression of CD25, CD28, and CD69; by cyclic
hanges in cell volume, and by intracellular cytokine
taining for interferon-.Figure 1. Experimeenotransplantation
Eight- to 10-week-old mice were exposed to sub-
ethal doses (300 cGy) of radiation 24 hours prior to
ransplantation. Cell suspensions were infused via tail
ein into recipient mice.
istopathologic Evaluation
Skin, liver, spleen, intestine, and lymph nodes
ere sampled immediately prior to engraftment anal-
sis. Specimens were coded so intervention group was
nknown. Tissues were ﬁxed overnight in 10% buff-
red formalin, dehydrated, embedded in parafﬁn, sec-
ioned, and stained with hematoxylin and eosin ac-
ording to standard protocols. Slides were evaluated
nd photographed by an experienced pathologist.
ata Collection and Statistical Analysis
Xenografted mice were sacriﬁced 7 to 8 weeks
ollowing transplantation (for limiting dilution analy-
is) or between days 23 and 28 (for recipients of TCD
CB with or without CD3/CD28 costimulated T
ells along with a parallel MNC group). Stable en-
raftment of HSC in these mice is thought to be
chieved at 6 to 8 weeks, and therefore that was felt to
e the most accurate time to evaluate HSC contribu-
ion in the limiting dilution analysis [17]. Subsequent
xperiments were designed to analyze level of early
ngraftment, which may represent HSC as well as
ultipotent (and later) progenitor cells—so earlier
ime points were chosen for analysis. Bone marrow
rom iliac crests, femurs, and tibiae were collected
rom each animal and incubated with ammonium chlo-
ide solution (StemCell Technologies) prior to cell sur-
ace staining. Cells were washed and incubated with
nti-human CD45-APC, CD19-PE, CD33-PerCP-
y5.5, and CD 3-FITC. The analysis protocol for
ells from NOG mice was changed to also include
rythroid cells, analyzed with CD45-APC, Glycoph-
rin A-PE, and CD36-FITC (BD Pharmingen, San
iego, CA, and Biolegend, San Diego, CA). FACSntal design.
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E. O. Hexner et al.1138as performed on a FACSCalibur (Beckton Dickin-
on, Fullerton, CA); 100,000 events per sample were
cquired. FACS data were analyzed using FloJo (Tree
tar, Ashland, OR); the live cell gate was determined
y forward scatter/side scatter properties and mice
ere considered engrafted if at least 0.5% of cells in
his gate were CD45 and demonstrated both human
yeloid and B lymphoid engraftment. Human ery-
hroid cells were deﬁned by double staining with
D36 and Glycophorin A. Human CD3 staining was
erformed to enumerate and control for any surviving
doptively transferred CD3 cells.
Level of engraftment data are presented as means
tandard error of the mean. Differences between level
f engraftment were analyzed using a 2-sided Stu-
ent’s t test or 1-way ANOVA when there were more
han 2 groups to analyze; analysis was performed using
MP software (SAS Institute, Cary, NC). SRC frequency
as determined using the single-hit Poisson model; a 2
est was applied to conﬁrm that the data were consistent
ith the model [17,18]. Data were analyzed using L-
alc software (StemCell Technologies).
ESULTS
CD of UCB Impairs Level of Engraftment
To test whether TCD adversely effects engraft-
ent in this xenograft model, thawed UCB MNCs
ere depleted of T lymphocytes by immunomagnetic
eparation of CD2 cells. Evaluation of cells follow-
ng separation showed that the efﬁciency of depletion
as 92% to 98%. In multiple experiments, TCD UCB
as consistently more enriched for CD34 cells when
ompared to UCB MNCs (Figure 2), although the dif-
igure 2. Infused UCB MNCs. CB MNCs were thawed, and for
CD recipients, depleted of CD2 cells immunomagnetically prior
o transplantation. Percentages of CD34 and CD3 cells in the
nfused product were evaluated by ﬂow cytometry, and a represen-
ative ﬂow cytogram is shown. TCD efﬁciency was 
97% and
D34 cells were consistently enriched in the TCD infused prod-cct compared to unmanipulated CB MNC.erence was not signiﬁcant (mean UCB MNC 0.38%
D34 versus TCD UCB 0.53% CD34; P .62 for
UCB units used in all experiments). Equal numbers
f viable TCD UCB or UCB MNCs were trans-
lanted into sublethally irradiated 8- to 10-week-old
OD/SCID-2m
/ mice, at 6 dose levels between 5
104 cells and 5 	 106 cells per mouse. There was no
ifference in survival of animals between groups. Over-
ll, mean engraftment in the MNC recipients was 4.70%
0.85% (range: 0-27.3%) versus 1.90% 0.87% in the
ecipients of TCD UCB (range: 0-10.6%) (P  .02;
igure 3A) despite the slight enrichment for CD34
ells in TCD UCB. The level of engraftment increased
n a dose-dependent manner, and linear regression
nalysis by the least squares method revealed that
ngraftment on a per cell basis (slope) was greater for
CB MNC than that for TCD UCB (Figure 3B).
uman CD3 cells were only detectable (
0.1%) in
mouse; this was a recipient of 5 	 106 MNCs, and
as the animal with the highest overall level of en-
raftment (27.3% CD45, 6% CD45CD3).
CID-Repopulating Activity in TCD UCB Is Not
ignificantly Lower than UCB MNCs
We also asked whether functional engrafting stem
ells were reduced in TCD UCB by performing a
imiting dilution analysis into recipients using a single
CB unit (Table 1). Five dose levels between 5 	 104
nd 5 	 106 cells were tested (4 to 8 mice/group; total
ice transplanted: 58, 54 survived to analysis). Mice
ere considered engrafted if ﬂow cytometry of ﬂushed
one marrow demonstrated more than 0.5% human
D45 cells in the forward scatter/side scatter gate
ith evidence for myeloid (CD33) and B lymphoid
CD19) engraftment (at least 0.1%) [19]. SRC fre-
uency was 1 in 3.03 	 105 for UCB MNCs (95%
onﬁdence interval [CI] 1 in 1.65 	 105  1 in 5.58 	
05), a ﬁgure that was only slightly higher and not
tatistically different from the SRC frequency of 1
n 5.39 	 105 measured in TCD UCB (95% CI 1 in
.82 	 105  1 in 1.03 	 106; P  .20). Thus,
lthough TCD clearly reduces the level of engraft-
ent (as assessed by the percent contribution of hu-
an hematopoietic cells in the mice) at all HSC doses,
he actual number of human HSCs contributing to
ematopoiesis is largely unchanged.
D3/CD28 Costimulated UCB T cells Restore
ngraftment Capacity
To retain cell surface CD3 for subsequent activa-
ion steps, TCD was performed by CD2 negative
election. CD2 is expressed on thymocytes, T, and
K cells, so it was possible that graft-facilitating ac-
ivity resided in any of these cellular compartments.
o conﬁrm that graft facilitating properties were spe-
iﬁc to mature T cells, and to test whether CD3/
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UCB, Engraftment and T Cells in Immunodeficient Mice 1139D28 costimulated T cells could facilitate engraft-
ent, we cotransplanted limiting numbers (8 	 105
ells) of TCD UCB cells with CD3/CD28 costimu-
ated T cells from the same UCB unit. T cells com-
rised 30% of the infused product, with a CD4 to
D8 ratio of 3 to 1, consistent with the original ratio
or the particular UCB unit as well as empiric pub-
ished data [1]. T cells were isolated and cultured in
he presence of anti-CD3 and anti-CD28 coated mag-
etic beads for 72 hours without exogenous cytokines,
nd then maintained in culture for 7 days. Cell surface
nalysis of expanded UCB T cells demonstrated that
5% of cells coexpressed CD3 and CD28; 93% of
ells were CD25bright; 9% expressed CD69; 2% ex-
ressed CD16; cells were negative for CD14 and
D19 (Figure 4A, left panels, and data not shown).
CB T cells could also be expanded directly from
resh or thawed UCB MNCs with 
92% CD3 pu-
ity; cell surface phenotype was similar with the ex-
eption that more expanded cells from MNCs ex-
ressed low levels of CD11b (12% versus 3% on
xpanded isolated T cells; Figure 4A, right panel).
Expanded T cells were infused along with TCD
CB and engraftment was assessed between day 23
nd 27. Given that NOD/SCID-2m
/ are known
o support the expansion of adoptively transferred
uman T cells, it was possible that differences in
uman CD45 expression represented only expanded
ature T cells [6]. To eliminate this potential con-
ounder, we measured engraftment by enumerating
otal percentage of human CD45 cells minus total
ercentage of human CD45CD3 cells. Engraft-
ent was signiﬁcantly higher in recipients of CD3/
D28 costimulated UCB T cells when compared to
ice receiving equal numbers of TCD UCB cells
CD45CD3: 5.94% 1.65% versus 0.29% 0.79%,
 .01), and remained so even when compared to
ooled data from groups of mice receiving as many as
million TCD UCB cells and UCB MNCs (Figure
B). Two mice receiving CD3/CD28 costimulated T
ells were evaluated at a later time point (56 days);
ean engraftment was not signiﬁcantly different when
able 1. SCID Repopulating Cell (SRC) Frequency in UCB MNC Is
ot Signiﬁcantly Different from TCD UCB
Live Cell Dose UCB MNC TCD UCB
5  104 0/3 (0%) 0/4 (0%)
1  105 4/8 (50%) 1/6 (16.7%)
5  105 7/8 (87.5%) 6/7 (85.7%)
1  106 5/6 (83.3%) 4/6 (66.7%)
5  106 2/2 (100%) 4/4 (100%)
RC frequency
(95% CI)
1 in 3.03  105
(1/1.65  105–
1/5.58  105)
1 in 5.39  105
(1/2.82  105–
1/1.03  106)
I indicates conﬁdence interval; UCB, umbilical cord blood; MNC,igure 3. Despite absent host barriers and more CD34 cells, the
evel of engraftment of TCD UCB is inferior to UCB MNC.
ercent human leukocyte engraftment was evaluated in BM from
ecipient mice between days 22 and 27 or 39 and 45 fol-
owing transplantation. A, Overall mean engraftment as assessed by
uman CD45 in UCB MNC recipients: 4.69%  0.85% (n  32,
ange: 0-27.3%) and TCD UCB: 1.90%  0.87% (range: 0-10.6%,
 31, P  .02). Diamonds represent mean (center) and 95%
onﬁdence intervals (top and bottom) for each distribution. B,
catter plot of percent human CD45 by dose of cells transplanted.
inear regression lines are shown for UCB MNC (solid line; linear
rediction human CD45  2.47  2.45 	 cell dose; R2: 0.54) and
CD MNC (interrupted line, linear prediction human CD45 
.56  1.25 	 cell dose; R2: 0.56). Limiting dilution analysis to
etermine functional stem cell numbers was performed using a
ingle unit of UCB at 5 dose levels between 5 	 104 and 5 	 106
ells (2 to 8 mice/group; total mice transplanted: 58, 54 survived to
nalysis) Animals with 
0.5% human CD45 cells, and 
0.1%
uman lymphoid (CD 19) and myeloid (CD33) cells in the
SC/SSC gate were considered to be engrafted. The difference inmononuclear cells; TCD, T cell depleted.
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E. O. Hexner et al.1140ompared to the mice evaluated at the earlier time
oint (CD45-CD3  6.82% versus 5.59%; P  .33).
Recipient mice of CD3/CD28 costimulated T
ells appeared clinically healthy. We examined liver,
pleen, skin, intestine, and remnant lymph nodes from
of the 7 recipients of CD3/CD28 costimulated T
ells, and there was no evidence of inﬂammation,
uggestive of xeno GVHD or other signiﬁcant pathol-
gy in any of the sampled tissues (Figure 4C). It
herefore appears that engraftment ability is restored
y add-back of CD3/CD28 costimulated T cells, and
hat xenoGVHD is uncommon.
acilitation of Early Multilineage Engraftment by
D3/CD28 Costimulated UCB T Cells Is
aintained in NOG Mice
We next asked whether early engraftment, repre-
enting in large part multilineage progenitor cells in the
raft, was speciﬁcally affected by supraphysiologic num-
ers of CD3/CD28 costimulated T cells in NOG mice.
ice received 1 million CB MNCs, TCD UCB cells, or
CD UCB cells with an additional 1 million CD3/
D28 costimulated T cells from the same UCB graft on
ay 9 of ex vivo culture. Lymphomyeloid as well
s erythroid engraftment (human CD36Glycophorin
igure 4. Coinfusion of CD3/CD28 activated UCB T cells with
ostimulated UCB T cells on day 7 of culture. Although transpl
D8-enriched cells, T cells could also be expanded from unpuri
anels demonstrate
93% purity of T cells in terms of CD3 express
f CD25 and CD28 in the entire population; CD11b was more high
xpanded from CD2 selected cells (black line); immunophenotype
nto mice was expanded from CD4 and CD8 isolated cells. B, Eng
ines represent means and standard error. C, Representative histopa
CB T cells showed no evidence of inﬂammation or signiﬁcant pathCD45 BM cells) was analyzed. Mean engraftment ef leukocytes (CD45CD3) was again higher in the
ecipients of TCD UCB  CD3/CD28 costimulated T
ells (7.54  1.73) compared to UCB MNC and TCD
B alone (4.94  1.41 and 4.88  1.41, respectively)
lthough the difference was not statistically signiﬁcant in
his relatively small cohort of animals (P  .44). There
as a striking increase in mean percent erythroid en-
raftment in recipients of CD3/CD28 costimulated T
ells (36.42  8.56; Figures 5A and B) compared to the
ther groups (TCD UCB: 9.30  6.99; UCB MNC
.52 6.99; P .02), which accounted in large part for
he overall multilineage engraftment advantage seen in
he recipients of CD3/CD28 costimulated T cells (sum
f CD45CD3 and CD45GlyACD36: 43.95 
.95 versus 14.81  8.12 in TCD UCB alone and
.46  8.12 for UCB MNC; P  .04; Figure 5B). The
ajority of human CD45 cells in bone marrow of
ecipients of UCB MNC were CD3 T cells, which
ere not present in signiﬁcant numbers in recipients of
CD UCB with or without CD3/CD28 costimulated T
ells (Figure 5A), demonstrating a survival advantage for
doptively transferred unmanipulated UCB T cells over
he cultured T cells, despite the presence of fewer T cells
n the original xenograft. Histopathologic examination
f liver and spleen of all mice analyzed (n  16) showed
UCB restores engraftment. A, Immunophenotype of CD3/CD28
D3/CD28 costimulated T cells were derived from CD4- and
Cs (fresh or thawed) with a comparable purity. Left and middle
9% CD4, 28.8% CD8, not shown). There was bright expression
essed on T cells derived from MNC (gray line) compared to T cells
herwise similar. The T cell product that was adoptively transferred
nt of CD45 cells minus adoptively transferred CD45CD3 cells.
c examination (liver, 20	) of recipients of CD3/CD28 costimulated
f sampled organs (4 of 7 recipient tissues examined, 0 of 4 affected).TCD
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UCB, Engraftment and T Cells in Immunodeficient Mice 1141ents, and evidence for liver xenoGVHD in 4 of 6 recip-
ents of UCB MNCs, 0 of 6 recipients of TCD UCB,
nd 1 of 4 recipients of TCD UCB with CD3/CD28
ostimulated T cells (Figure 5C).
ISCUSSION
In this study we sought to test the speciﬁc role of
ature UCB T cells on engraftment of UCB into
OD/SCID-2m
/ mice. We were interested in the
verall level of engrafted human cells as a continuous
ariable, as well as a quantitative assessment of func-
ional stem cell numbers as assessed by a limiting
ilution analysis (Figure 1). We found that UCB
rafts depleted of T cells have inferior levels of en-
raftment when compared to UCB MNCs trans-
lanted into NOD/SCID-2m
/ mice. Although the
verall level of engraftment was signiﬁcantly lower for
ecipients of TCD UCB, SRC frequency was not
igniﬁcantly different, suggesting that T cells augment
ematopoiesis at stages beyond the stem cell. Finally,
e found that engraftment capacity could be restored
y add-back of ex vivo CD3/CD28 costimulated T
ells from the same UCB unit; this property was
aintained in NOG xenografts as well.
igure 5. Facilitation of early multilineage engraftment by CD3/C
rythroid engraftment in recipients of TCD UCB with costimul
ngraftment advantage in this cohort of mice (n  6 per group; 16
rom representative mice gated on live cells: x-axes: human CD45
ajority of human CD45 cells in recipients of UCB MNC we
omposite sum of CD45CD3 cells together with the GlyACD
f a recipient of TCD UCB with costimulated CD3/CD28 UCB
H&E; 10	) showing mild periportal and intrahepatic inﬂammatorBecause depletion of T lymphocytes adversely in- ouences engraftment of UCB into NOD/SCID-
2m
/ recipients who lack T, B, and NK cells, our
esults suggest that T cells have a role beyond over-
oming immune barriers in HSCT. Transplanting
imited numbers of cells, we have demonstrated that T
ell replete UCB results in a more than 2-fold increase
n the level of engraftment when compared to TCD
CB. However, although the level of engraftment of
CD UCB into NOD/SCID-2m
/ mice is signif-
cantly impaired, quantitative assessment of SRC fre-
uency by limiting dilution analysis did not reveal
igniﬁcant differences between TCD UCB and UCB
NCs. This suggests that the differences in the level
f engraftment are explained by accessory cell inﬂu-
nces at the progenitor stage or beyond. Of course, it
s possible that we have failed to identify a modest
ifference in SRC frequency that a larger sample size
ight have detected, but our data clearly show a
ositive effect on the level of engraftment, beyond the
evel of the SRC. Preservation of total cell numbers
ook priority in our experimental design over normaliza-
ion for CD34 cells, but it is worth noting that CD34
ells were slightly but consistently enriched in the TCD
CB grafts, although the difference was not statistically
igniﬁcant. Thus, it is possible that on a per SRC basis,
ostimulated UCB T cells is maintained in NOG mice. A, Marked
3/CD28 UCB T cells accounted, in large part, for the overall
mice survived to analysis). Contour plots (A) of bone marrow cells
: Glycophorin A (A, top panels) and CD3 (A, lower panels). The
nded adoptively transferred CD3 cells. B, Engraftment of the
ls. C, Photomicrographs of spleen (H&E: left, 10	, middle, 40	)
s demonstrating extramedullary hematopoiesis. Right panel: liver
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E. O. Hexner et al.1142nce between TCD UCB and UCB MNCs, both in
erms of level of engraftment and SRC frequency.
Most importantly, we found in this preclinical
odel that CD3/CD28 costimulated UCB T cells
nfused at the time of transplantation possess graft-
acilitating properties. TCD UCB coinfused with
hysiologic numbers of CD3/CD28 costimulated T
ells restored and enhanced engraftment. When sup-
aphysiologic numbers of CD3/CD28 costimulated T
ells were adoptively transferred into NOG mice, graft
acilitation was maintained in terms of early engraft-
ent. Effects were particularly striking in the erythroid
ompartment, which might reﬂect the erythroid stim-
lating (burst promoting) activities of granulocyte-
onocyte colony stimulating factor (GM-CSF) and
nterleukin-3 (IL-3), whose secretion is markedly in-
reased in costimulated T cells [20-22]. Because GM-
SF and IL-3 do not act at the stem cell level itself, it
ay be that T cells enhance engraftment by acting
nly on multipotent or later stage progenitor cells.
Somewhat surprising in the NOG recipients of
CB MNC was the predominance of adoptively
ransferred human CD3 cells, suggesting that this
odel is particularly permissive for T cell expansion,
omeostatic proliferation, or otherwise, and that the
redominantly na¨ive T cells in UCB MNC have an in
ivo survival advantage over CD3/CD28 costimulated
cells. Although only a rigorous clinical phase 1
afety study can truly address the true toxicity of these
ells in terms of GVHD, it is nonetheless reassuring
hat evidence for xenoGVHD was rare in recipients of
D3/CD28 costimulated T cells.
Goodman et al. [23,24] ﬁrst showed in the 1960s
hat thymocytes enhanced hematopoiesis in a rat
SCT model, and, somewhat surprisingly, that this
roperty was present and uniquely potent in tolerant
hymocytes. In 1978, it was shown that T cells were
equired for the proliferation of primitive red blood
ell precursors in vitro, and that a soluble factor from
he T cell culture was responsible for this effect [25].
he starkest evidence for a critical role of T cells in
ematopoiesis in vivo came in the 1980s, with clinical
utcomes from TCD bone marrow allografts, which
ere found to have a disappointingly high rate of graft
ailure: 10%-30% in recipients of HLA identical
CD grafts and 50%-70% in recipients of HLA mis-
atched TCD grafts [26,27]. In the same decade it
as shown that adoptive transfer of buffy coat cells
ould overcome graft rejection and increase overall
urvival (OS) in patients undergoing HSCT for severe
plastic anemia [28].
Mature immune cells have been implicated more
ecently by Kim et al. [29] in preclinical models ex-
loring the fate of transplanting 2 UCB grafts into
OD/SCID mice. When equal numbers of total
NCs from 2 UCB units are transplanted, 1 unitredominates. Interestingly, if the UCB grafts are ﬁrst oepleted of lineage committed cells (including T cells,
K cells, B cells, and mature myeloid cells), there is
alanced coengraftment of both UCB units. Similarly,
otransfer of bone marrow derived mesenchymal stem
ells—cells thought to possess immunosuppressive
roperties—from a separate, third-party source will
lso result in balanced coengraftment, even when total
NCs from 2 UCB units are transplanted. Taken
ogether, these observations suggest that the level of
ngraftment of UCB HSCs is a function of mature
ccessory cells in the graft, and that the predominance
f 1 graft over another is likely immune mediated.
ecent clinical studies by Barker et al. [30] at the
niversity of Minnesota are consistent with these
odels: when 23 subjects underwent HSCT as recip-
ents of 2 partially mismatched unrelated UCB units,
n all cases 1 UCB unit ultimately predominated with
pparent loss of the other graft. Neither the number
f CD34 cells nor total cell number in the graft
redicted which graft would predominate, although
here was a direct association between the number of
cells and the UCB unit with durable engraftment.
n addition, the median time to engraftment (23 days)
as meaningfully shorter than that in most published
eports of UCB HSCT. Although the mechanisms
nderlying this observation have not been identiﬁed,
ne interesting possibility is that an alloresponse be-
ween UCB units mediates not only rejection of 1
raft, but also actually accelerates engraftment of the
raft fated to survive, either directly through speciﬁc
cell interactions or via nonspeciﬁc cytokine-medi-
ted mechanisms. The dual UCB experience is en-
ouraging, and represents an important potential new
pproach to reducing transplant related mortality
TRM) of UCB HSCT. That only 1 UCB unit ulti-
ately engrafts raises the possibility that functional
tem cell activity is modiﬁable by accessory cells in the
raft, and a more precise understanding of these
echanisms might also enhance engraftment of single
CB units.
Several lines of evidence suggest that both cyto-
ine and contact dependent pathways are mechanisti-
ally involved in the establishment of hematopoiesis in
enograft as well as mouse HSCT models [31]. Our
bservation suggests that T cells are key accessory
ells in this model. Mechanistically, Adams et al. [32]
ound that UCB CD8 cells could facilitate engraft-
ent of UCB-derived progenitors in a contact-depen-
ent manner, and suggest that they inﬂuence the re-
ponse of CD34 cells to chemotactic gradients.
ouse HSCT models suggest that although CD8 T
ells lacking cytotoxic effector mechanisms can sup-
ort the early establishment of progenitor cells, long-
erm engraftment of mature peripheral blood cells
equires intact perforin [33,34]. Whether graft facili-
ation is inherent to canonical CD8 T lymphocytes
r to other CD8 populations in this model system is
u
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UCB, Engraftment and T Cells in Immunodeficient Mice 1143nknown: CD8lo cells lacking a T cell receptor
TCR) have been termed facilitating cells and en-
ance engraftment of murine HSCs in mouse models;
hese cells were more recently further deﬁned by Fu-
ier-Vivier et al. [35-37] as plasmacytoid precursor
endritic cells, and also posess tolerogenic properties.
he functional importance of these cells in clinical
SCT has not yet been determined, and in fact, UCB
rafts have proportionally more CD8lo TCR cells
ompared to blood or marrow graft sources, despite
he impaired engraftment properties of UCB [38].
T cell depletion did not signiﬁcantly decrease
RC frequency, which may help to pinpoint the early
rogenitor period as the critical window for T cell
elp. In (nontransplant) studies of normal hematopoi-
sis, Monteiro et al. [39] showed that T cell-deﬁcient
ice are neutropenic but have an accumulation of
mmature myeloid cells in bone marrow, and found
hat T cell infusions can restore normal hematopoie-
is. Interestingly (despite the intense interest and sub-
tantial data in the transplant literature on the graft-
acilitating effect of the CD8 compartment), in this
odel only CD4 cells could be shown to rescue
hese mice, whereas CD8 cells could not [32,35-
7,40].
We found that CD3/CD28 costimulated UCB T
ells were potent graft-facilitating cells, establishing
roof of principle for testing the intervention in clin-
cal UCB transplantation. This model will also be
seful for evaluating dose responses to supraphysi-
logic numbers of CD3/CD28 costimulated T cells.
ere we only tested engraftment of UCB, so it is not
ossible to address whether unmanipulated UCB T
ells are indeed “defective” with respect to graft facil-
tation. The interpretation that CD3/CD28 activated
CB T cells facilitate engraftment is consistent with
he observation by Fugier-Vivier et al. that their
D8loTCR facilitating cells are most effective in an
ctivated state. It is possible that microenvironmental
aracrine factors might explain such ﬁndings: to date,
here is no cytokine, alone or in combination, that can
upport in vitro hematopoietic colony formation as
ell as lymphocyte-conditioned medium, suggesting
hat there are yet to be identiﬁed soluble factors pro-
uced by activated T cells that augment hematopoiesis
41]. IL-17, a product of activated T cells, deserves
urther study: it is known to expand hematopoietic
rogenitors and enhance granulopoiesis; more re-
ently, an IL-17 receptor-deﬁcient mouse was found
o have impaired hematopoietic recovery following
rradiation [42-44].
In summary, we have shown that T cells augment
ematopoiesis in immunodeﬁcient UCB xenograft
odels. Engraftment is increased in the presence of T
ells, whereas functional numbers of stem cells are
nchanged, suggesting that T cells support later stages
f hematopoiesis. Our results suggest that T cellsacilitate engraftment beyond simply overcoming host
arriers, and that CD3/CD28 costimulated UCB T
ells possess graft-promoting properties, representing
potential translational approach for facilitating en-
raftment in UCB HSCT.
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